Recruitment of cancer patients by LCRN Subspecialty: Haem Onc & Lymphoma

Recruits per 100,000 Population

1

Gloucester

shire Hospita

ls NHS F

oundation Tr

ust

Great W

estern

Hospita

ls NHS F

oundation Tr

ust

Royal Unite

d Hospita

ls Bath

NHS Foundati

on Trust

Taunton an

d Somers

et NHS F

oundation Tr

ust

Universi

ty Hosp

itals B

ristol N

HS Foundati

on Trust

Weston Area

Health

NHS Trust

02468

1012141618

3 28

1 3 1

9

8

Recruitment to Lymphoma Cancer studies by study design type by CRN: West of England partner organisations 2014/15

Lymphoma Group - Interventional Lymphoma Group - Observational

Trusts

Recr

uitm

ent

Gloucester

shire Hospita

ls NHS F

oundation Tr

ust

Great W

estern

Hospita

ls NHS F

oundation Tr

ust

North Bris

tol NHS T

rust

Royal Unite

d Hospita

ls Bath

NHS Foundati

on Trust

Taunton an

d Somers

et NHS F

oundation Tr

ust

Universi

ty Hosp

itals B

ristol N

HS Foundati

on Trust

Yeovil

District

Hospita

l NHS F

oundation Tr

ust0

5

10

15

20

25

1 2 1 32

22

61

21

Recruitment to Lymphoma Cancer studies by study design type by CRN: West of England partner organisations 2015/16 -YTD

Lymphoma Group - Interventional Lymphoma Group - Observational

Trusts

Recr

uitm

ent

Gloucester

shire

Hospita

ls NHS F

oun...

Great W

estern

Hospitals N

HS Found...

NHS Bath

and North

East

Somers

...

North Bris

tol NHS T

rust

Royal Unite

d Hospitals B

ath NHS F

o...

Taunton an

d Somers

et NHS F

ounda...

Universi

ty Hospita

ls Bris

tol NHS F

o...

West

on Area Hea

lth NHS T

rust

Yeovil

Distric

t Hosp

ital N

HS Founda..

.0

50

100

150

200

250

300

350

400

450

82 76 31 24 111 48 418 27 72

1 1

1 1

1

1

7

2

Recruitment to non Cancer Haematology studies by study design type by CRN: West of England partner organisations 2014/15

Observational Interventional BothTrusts

Recr

uitm

ent

Gloucester

shire Hospita

ls NHS F

oundation Tr

ust

Great W

estern

Hospita

ls NHS F

oundation Tr

ust

NHS Bath

and North

East S

omerset

CCG

North Bris

tol NHS T

rust

Royal U

nited Hosp

itals B

ath NHS F

oundation Tr

ust

Taunton an

d Somers

et NHS F

oundation Tr

ust

Universi

ty Hosp

itals B

ristol N

HS Foundati

on Trust

Weston Area

Health

NHS Trust

Yeovil

Distric

t Hosp

ital N

HS Foundati

on Trust

0

20

40

60

80

100

120

140

7

44

6 933 37

125

9 20211

1

Recruitment to non Cancer Haematology studies by study design type by CRN: West of England partner organisations 2015/16 - YTD

Observational Interventional Both

Trust

Recr

uitm

ent

MYELOMA 1st line

MYELOMA XI Randomised comparisons of thalidomide, lenalidomide, bortezomib, carfilzomib combinations and maintenance lenalidomide UHB/NBT/C+G

Cardamon Carfilzomib/Cyclo/Dex with maintenance carfilzomib in untreated ASCT-eligible patients In set-up RUH

TEAMM Randomized, double-blind, phase III trial of levofloxacin vs placebo in newly diagnosed MM requiring therapy RUH/NBT/Swindon/C+G

Millennium Ixazomib maintenance vs placebo after induction therapy if not having ASCT. UHB In set-up RUH/NBT

2nd line MUK5

CCD (cyclo/carfilz/dex) vs CVD (cyclo/bortezomib/dex) as second line therapy

UHB- JB

MUK8 Relapsed disease randomised trial UHB-JB in set-up

Amyloid Prothena

Mab against amyloid protein

UHB-JB/JG in set-up

LYMPHOMA 1st line

MCL biobank All patients newly diagnosed with mantle cell lymphoma, whether requiring therapy or not UHB/NBT/C+G/Taunton

ENRICH Older MCL R-ibrutinib vs R-chemo (CHOP or bendamustine at investigator’s discretion) EOI C+G/UHB

Chemo-T CHOPx6 vs GEM-P x4 Taunton /C+G/Yeovil

ReModL-B Adding bortezomib to R-CHOP on basis of GEP – closing June 2015 C+G/RUH/Swindon

R2W FCR vs bortezomib/cyclo/ritux (BCR) in previously untreated Waldenstroms RUH/Taunton

MAPLE FL 3b/DLBCL – observational study of molecular profiling ? new agents in future RUH/Swindon

EBV Observational study in EBV assoc T-cell/NK malignancies. Taunton

PACIFICO R-CVP vs FCR lite in older patients with untreated follicular NHL Weston/RUH

NCRN 3171 Double-blind RCT ritux vs biosimilar x4 in untreated, low tumour burden FL. RUH

INCA Newly diagnosed DLBCL with cardiac contra-indications to anthracycline – IO-R-CVP vs Gem-R-CVP UHB /NBT/RUH

NHL TYA Registry study for all NHL diagnosed age 15-29 UHB in set up LL

Relapsed/refractory

LEGEND Lenalidomide/gemcitabine/methylpred (L-R-Gem) vs R-GEM-P in relapsed/refractory DLBCL Taunton – S Bolam

ARROVEN Relapsed/refractory HL or ALCL – observational study C+G

LYMRIT-37-01 Phase II – Betalutin (CD37 antibody with radio-isotope) in relapsed FL I-IIIA, marginal zone, SLL, lymphoplasmacytic, mantle cell lymphoma UHB – Matt Beasley

LYMRIT Betalutin in r/r FL UHB in set-up MB

LYMRIT Betalutin in r/r/ DLBCL UHB in set-up MB

SADAR Selinexor in r/r DLBCL C+G in set up

CLL

1st line FLAIR

FCR vs R-ibrutinib aged 18-75. >20% p53 deletion by FISH excluded.

UHB/NBT/RUH/Taunton, in set-up C+G

Rialto In less fit patients Ofatumumab/chlorambucil vs Ofatumumab/bendamustine, plus idelalisib vs placebo Weston/RUH/Swindon/C+G/Yeovil

GALACTIC GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL NBT- Sophie Otton, in set-up RUH/C+G

ALL 1st line UKALL2011

Newly diagnosed, Ph-ve ALL patients, aged less than 25

UHB – John MoppettRUH in set-up

UKALL14 Newly diagnosed ALL patients, aged 25-65 (Ph+ve patients aged 19-65 are eligible) UHB – David MarksRUH/C+G/Taunton

UKALL60+ Phase 2 study in newly diagnosed patients with ALL aged over 60 (or over 55 unsuitable for UKALL14) UHB – DM/TauntonIn set-up C+G

GLOBALL Coagulation in newly diagnosed ALL - observational UHB - CB

2nd line TOWER

Blinatumomab vs standard care in relapsed/refractory Ph- ALL

UHB – DM

Leukaemia/MDS

WT1 Phase 1/2 WT1 TCR gene therapy. AMLnot for allograft - 2nd CR, or 1st CR in poor risk or >60; CML resistant to imatinib+2nd gen TKI not suitable for SCT UHB – DM

AML 1st line AML 18

AML/RAEB-2 patients, usually aged over 60, fit for intensive therapy

UHB-PM / C+G, In set-up RUH

AML 19 Newly diagnosed patients with AML, aged under 60 UHB in set-up –PM/ RUH/Taunton/C+G

AML LI-1 Newly diagnosed AML (not APL) or RAEB-2, not suitable for intensive therapy, aged over 60. UHB – PMSwindon/C+G/Yeovil

Cytarabine sens Observational study in all AML patients – blood or marrow samples required UHB – PM

APL coag Pilot study – understanding and managing the coagulopathy in APL Taunton

WT-1 Gene therapy study for high risk MDS/AML UHB-RP in set up

2nd line AMBIT

AC-220 vs standard care in patients with first relapse of FLT3-ITD positive AML

UHB – Priyanka Mehta

CML SPIRIT 3

On hold centrally

UK-TARGET-CML EOI C+G

Transplant

UK-POSTAGE Prospective study of 2nd line therapy for acute GVHD, can have had up to 3 weeks steroid therapy for GVHD UHB –JG

FIGARO AML/MDS patients having RIC allo SCT – randomised comparison of FLAMSA-BU vs standard conditioning UHB – RP

Pro T4 Prophylactic transfer CD4+ lymphocytes in patients undergoing FMC sib allo for haematological cancer (2:1 randomisation DLI vs none) UHB – SR

UK haplo Haplo SCT (RIC or myeloablative) UHB – RP

Aztec Azacytidine for GVHD UHB – RP in set-up

MDS

MDS Bio Observational study in all patients with MDS/CMML – please consider when performing a marrow biopsy where MDS is a possible diagnosis UHB – PM, NBT – AW, C+G

Aza-MDS Azacitidine vs supportive care in patients with transfusion dependent MDS with PLT <75, IPSS score 0-1.0 UHB – Priyanka Mehta

HR-Elastic

REDDS

De-iron Phase 2 study of deferasirox at early iron loading in transfusion-dependent MDS Taunton

MDS-010 Non-interventional study of Low/INT-1 MDS patients, transfusion dependent, with isolated 5q- In set-up RUH

MPN

Majic Ruxolitinib vs best care with PV + high risk feature(>60, previous thrombosis, splenomegaly, PLT >1000, DM /↑bp) resistant to/intolerant of OHurea RUH/Swindon/Taunton/C+G

MPD-RC114 Ruxolitinib in myelofibrosis pre allograft UHB-JG in set-up

Other

PNH registry Patients of any age with a diagnosis of PNH, or a detected PNH clone. UHB – Priyanka Mehta

Brightlight Young people aged 13-24 with cancer diagnsosi, recruited within 4 months of diagnosis RUH

InCite Case-control study of IC haemorrhage in thrombocytopenic haematology patients RUH

Zoster002 VZV vaccine therapy in ASCT patients Swindon

Zoster039 VZV vaccine in haematology patients Swindon

TREATT Trial to Evaluate Antifibrinolytic Therapy in Thrombocytopenia UHB – Andrew Mumford

Non-cancer

ITP registry All patients diagnosed at any time, need consent and 4 extra bottles EDTA blood, PLT <100 UHB – CB/RUH/Taunton. In set-up NBT/Yeovil

Mole Ix anaemia UHB – Charlotte Bradbury/ Taunton